Efficient Screening of Covariates in Population Models Using Wald's Approximation to the Likelihood Ratio Test

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Pharmacokinetics and Pharmacodynamics

• Publication date

  2001-06-01

• Fields of study

  Medicine, Mathematics

• Identifiers
  DOI 10.1023/A:1011579109640PMID 11468940
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Introduction to Linear Regression Analysis

  2007cited by this paper
• Regressions by Leaps and Bounds

  2000cited by this paper
• Automated Covariate Model Building Within NONMEM

  1998influential reference
• Bayesian Model Averaging in Proportional Hazard Models: Assessing the Risk of a Stroke

  1997influential reference
• Inverse Nonlinear Pharmacokinetics of Total and Protein Unbound Drug (Oxaprozin): Clinical and Pharmacokinetic Implications

  1996cited by this paper
• Linear and Nonlinear Models for the Analysis of Repeated Measurements

  1996cited by this paper
• A note on the use of Laplace's approximation for nonlinear mixed-effects models

  1996cited by this paper
• Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

  1992influential reference
• Estimating the Dimension of a Model

  1978cited by this paper
• Efficient Screening of Nonnormal Regression Models

  1978influential reference
• Comparing Subset Regression Procedures

  1978cited by this paper
• A new look at the statistical model identification

  1974cited by this paper
• Tests of statistical hypotheses concerning several parameters when the number of observations is large

  1943cited by this paper

• Covariate Model Selection Approaches for Population Pharmacokinetics: A Systematic Review of Existing Methods, From SCM to AI

  2025cites this paper
• Stochastic Gates for Covariate Selection in Population Pharmacokinetics Modeling

  2025cites this paper
• Covariate modeling in pharmacometrics: General points for consideration

  2024cites this paper
• Go beyond the limits of genetic algorithm in daily covariate selection practice

  2023cites this paper
• Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia

  2023influential citation
• Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.

  2022cites this paper
• A randomised controlled trial of a novel tramadol chewable tablet: pharmacokinetics and tolerability in children

  2022cites this paper
• SAMBA: A novel method for fast automatic model building in nonlinear mixed‐effects models

  2022cites this paper
• Evaluation of covariate effects using variance-based global sensitivity analysis in pharmacometrics

  2021cites this paper
• A Modified Hybrid Wald’s Approximation Method for Efficient Covariate Selection in Population Pharmacokinetic Analysis

  2021cites this paper
• A novel method based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: The COSSAC approach

  2021cites this paper
• Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib

  2021cites this paper
• Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy

  2021cites this paper
• Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer

  2020cites this paper
• Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?

  2020cites this paper
• Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs

  2020cites this paper
• Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?

  2020cites this paper
• Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma

  2019cites this paper
• Operating characteristics of stepwise covariate selection in pharmacometric modeling

  2019cites this paper
• Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation

  2018cites this paper
• Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema

  2018cites this paper
• Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

  2018cites this paper
• Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors

  2018cites this paper
• Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL‐23, in Patients with Moderate to Severe Plaque Psoriasis

  2018cites this paper
• Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight

  2017cites this paper
• Efficient Computation of Reduced Regression Models

  2017influential citation
• Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years

  2016influential citation
• Exposure–response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS‐5565) in patients with diabetic peripheral neuropathic pain

  2016cites this paper
• Population Exposure‐Response Modeling of Naloxegol in Patients With Noncancer‐Related Pain and Opioid‐Induced Constipation

  2016cites this paper
• Efecto de las concentraciones de ritonavir en la farmacocinética de atazanavir: aplicación de técnicas de modelado y simulación farmacocinético poblacional /

  2016cites this paper
• Should I Bridge or Should I Bond? Social Capital Strategies and Contingencies

  2016cites this paper
• Covariate selection in pharmacometric analyses: a review of methods

  2015cites this paper
• Population pharmacokinetics of pegaptanib sodium (Macugen®) in patients with diabetic macular edema

  2015cites this paper
• Population Pharmacokinetics Analysis of Vigabatrin in Adults and Children with Epilepsy and Children with Infantile Spasms

  2014cites this paper
• Associations of food insecurity with body mass index among baby boomers and older adults

  2014cites this paper
• 5. Model Building

  2014cites this paper
• Concordance between criteria for covariate model building

  2014cites this paper
• Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance

  2013cites this paper
• Dosing Celecoxib in Pediatric Patients With Juvenile Rheumatoid Arthritis

  2012cites this paper
• Population Pharmacokinetics of Pegaptanib in Patients With Neovascular, Age‐Related Macular Degeneration

  2012cites this paper
• Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.

  2012cites this paper
• Covariate Pharmacokinetic Model Building in Oncology and its Potential Clinical Relevance

  2012cites this paper
• Model Validation Methods of Population Pharmacokinetic Models

  2012cites this paper
• Model Based Analysis of Ethnic Differences in Type 2 Diabetes

  2012cites this paper
• Confirmatory analysis for phase III population pharmacokinetics

  2011influential citation
• Model-Based Approach for Optimization of Atazanavir Dose Recommendations for HIV-Infected Pediatric Patients

  2011cites this paper
• Apports des modèles non linéaires à effets mixtes dans l'étude de la variabilité pharmacocinétique et pharmacodynamique des médicaments antithrombotiques

  2011cites this paper
• A Fast Method for Testing Covariates in Population PK/PD Models

  2011cites this paper
• Nonlinear Mixed Effects Models: Theory

  2011cites this paper
• Diagnostics for nonlinear models with application to population pharmacokinetic modeling

  2010influential citation
• Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model

  2010cites this paper
• Population Pharmacokinetics of Sildenafil in Term Neonates: Evidence of Rapid Maturation of Metabolic Clearance in the Early Postnatal Period

  2009cites this paper
• Sample Size/Power Calculations for Population Pharmacodynamic Experiments Involving Repeated-Count Measurements

  2009cites this paper
• Informative study designs to identify true parameter–covariate relationships

  2009cites this paper
• The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data

  2008cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 59 Covariate Model Building in Nonlinear Mixed Effects Models

  2007cites this paper
• The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models

  2007cites this paper
• Covariate Model Building in Nonlinear Mixed Effects Models

  2007cites this paper
• Impact of modelling intra‐subject variability on tests based on non‐linear mixed‐effects models in cross‐over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients

  2007cites this paper
• Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software

  2007cites this paper
• A Genetic Algorithm-Based, Hybrid Machine Learning Approach to Model Selection

  2006influential citation
• Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.

  2006cites this paper
• Effect of NONMEM minimization status and number of replicates on bootstrap parameter distributions for population pharmacokinetic models: A case study

  2005cites this paper
• Evaluation by simulation of tests based on non‐linear mixed‐effects models in pharmacokinetic interaction and bioequivalence cross‐over trials

  2005cites this paper
• On some “disadvantages” of the population approach

  2005cites this paper
• Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study

  2005cites this paper
• Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

  2005cites this paper
• What is the best size descriptor to use for pharmacokinetic studies in the obese?

  2004cites this paper
• A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data

  2003cites this paper
• Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmacokinetics and Drug Therapy presented at Uppsala University in 2002

  2002cites this paper
• Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

  2002cites this paper
• ! " ! # Blockin Blockin Blockin$ % Evaluation of Type I Error Rates When Modeling Ordered Categorical Data in Nonmem, in Manuscript Models Specific to Time-varying Covariates; Application in Population Pharmacokinetic-pharmacodynamic Model Building, in Manuscript Pharmacokinetic Modeling of Saturabl

  year unknowncites this paper